Streetbeat News

Regulatory

NYCB

New York Community Bancorp's Board recommends shareholders to vote for several proposals, including a reverse stock split by a ratio of 1-3, increasing authorized shares, and approving executive compensation. Other proposals involve ratifying KPMG LLP as the independent auditor, amending the certificate of incorporation, waiving certain voting restrictions for affiliates of Liberty 77 Capital and Reverence Capital Partners, and approving a March 2024 capital raise in compliance with NYSE rules.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 1:19 pm

EIS

SPY

The United States along with 17 other nations have issued a call to Hamas for the release of hostages in Gaza, as reported by Reuters. This international plea highlights the ongoing geopolitical tensions in the region and could have implications on global markets.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 12:59 pm

CAT

Caterpillar anticipates ongoing weak economic conditions in Europe and a softening economy in the Asia-Pacific region, excluding China, according to Bloomberg.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 12:49 pm

ETN

Eaton has been awarded $26.6 million in federal tax credits to support its U.S. manufacturing and workforce training programs, aimed at advancing clean energy projects. This financial incentive is expected to bolster Eaton's position in the clean energy sector, enhancing its manufacturing capabilities and workforce skills in alignment with growing environmental sustainability trends.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 12:43 pm

APLM

Apollomics Inc. announced that its partner Avistone received approval from China's NMPA for vebreltinib as a treatment for gliomas with MET fusion gene. This marks vebreltinib as the first c-Met inhibitor approved for CNS tumors with c-Met alteration. The approval is based on the positive results of the FUGEN study, showing significant improvement in median overall survival for patients with ZM fusion-positive glioma. Apollomics retains rights outside China, with ongoing global studies showing similar promising results.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 12:42 pm

MDWD

MediWound Ltd. (NASDAQ:MDWD) announced it will present new data from EscharEx Phase II studies at three major wound care conferences in May 2024. The data includes comparative analyses between EscharEx and SANTYL, demonstrating EscharEx's superiority in enzymatic debridement for chronic wounds. These findings support the design and endpoints of the upcoming Phase III study, expected to begin in H2 2024, highlighting EscharEx's potential to significantly advance wound care.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 12:32 pm

NVDA

ORCL

Oracle announced the availability of NVIDIA AI Enterprise on Oracle Cloud Infrastructure Supercluster in the Oracle U.S. Government Cloud region, enhancing sovereign AI capabilities for U.S. government customers. This collaboration between Oracle and NVIDIA provides a secure, scalable platform for developing and deploying AI solutions, leveraging NVIDIA's H100 and A100 Tensor Core GPUs for high-performance computing and AI applications. The service aims to meet stringent security and compliance requirements, offering a comprehensive suite of tools for AI development and deployment.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 12:21 pm

XOMA

Xoma Corporation has earned $9 million due to the FDA's accelerated approval of Day One's Ojemda (Tovorafenib) for treating relapsed or refractory BRAF-Altered Pediatric Low-grade Glioma. This milestone payment is a significant financial event for Xoma, highlighting the company's involvement in the development and success of Ojemda.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 12:07 pm

TCN

Tricon Residential Inc. (NYSE:TCN) has received Investment Canada Act approval for its acquisition by Blackstone Real Estate for $11.25 per share in cash. The transaction, already approved by shareholders and regulatory bodies, is expected to close by May 1, 2024. Following the closure, Tricon's shares will be delisted from the NYSE and TSX, and the company will deregister from the U.S. Exchange Act.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 12:06 pm

SNGX

Soligenix has expanded its patent protection for its Filovirus vaccine platform, including thermostabilized Ebola vaccines MarVax and SuVax, to the UK and South Africa. The extension also covers a nanoemulsion adjuvant compatible with lyophilization.

Portfolio Pulse from Benzinga Newsdesk

April 25, 2024 | 11:40 am